Product Review - Crizotinib use in NSCLC

This review discusses the evidence in support of the use of oral crizotinib for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Independent commentary by Associate Professor Ben Solomon a Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia.

Please login below to download this issue (PDF)